董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Francis | 男 | Director | 70 | 41.62万美元 | 10.81 | 2026-12-03 |
| Jerel Banks | 男 | Chairman of the Board and Chief Executive Officer and Director | 51 | 651.63万美元 | 144.38 | 2026-12-03 |
| J. Kevin Buchi | 男 | Director | 71 | 41.56万美元 | 15.99 | 2026-12-03 |
| Edward Smith | 男 | Director | 55 | 41.01万美元 | 10.78 | 2026-12-03 |
| Kishen Mehta | 男 | Director | 41 | 39.43万美元 | 7.00 | 2026-12-03 |
| David Friedman | 男 | Director | 51 | 33.21万美元 | 3.50 | 2026-12-03 |
| Sharon Mates | 女 | Director and Lead Independent Director | 72 | 77.20万美元 | 6.35 | 2026-12-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Megan Boston | 女 | Chief Financial Officer and Secretary | 54 | 316.74万美元 | 55.50 | 2026-12-03 |
| Jerel Banks | 男 | Chairman of the Board and Chief Executive Officer and Director | 51 | 651.63万美元 | 144.38 | 2026-12-03 |
| Sophie Mukadam | 女 | Chief Operating Officer | 45 | 670.64万美元 | 30.42 | 2026-12-03 |
董事简历
中英对照 | 中文 | 英文- Peter Francis
-
Peter Francis自2006年2月成为公司的董事长。1993年起 Francis先生在Francis Abourizk Lightowlers（一家商业和技术律师事务所）和位于澳大利亚墨尔本（Melbourne, Australia）的办事处的合伙人。他是知识产权和许可领域的法律专家，为公司和研究机构提供法律咨询。Francis先生完成了他在莫纳什大学（Monash University）法律与判例课程。
Peter Francis has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993, Mr. Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr. Francis completed his studies in law and jurisprudence at Monash University. - Peter Francis自2006年2月成为公司的董事长。1993年起 Francis先生在Francis Abourizk Lightowlers（一家商业和技术律师事务所）和位于澳大利亚墨尔本（Melbourne, Australia）的办事处的合伙人。他是知识产权和许可领域的法律专家，为公司和研究机构提供法律咨询。Francis先生完成了他在莫纳什大学（Monash University）法律与判例课程。
- Peter Francis has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993, Mr. Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr. Francis completed his studies in law and jurisprudence at Monash University.
- Jerel Banks
-
Jerel Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
Jerel Banks has been a Director since October 2016, Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. Dr. Banks' experience in the healthcare industry and finance provides valuable experience and guidance to the Board. - Jerel Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
- Jerel Banks has been a Director since October 2016, Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. Dr. Banks' experience in the healthcare industry and finance provides valuable experience and guidance to the Board.
- J. Kevin Buchi
-
J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010, Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. - J. Kevin Buchi，他于2013年8月加入Benitec Biopharma Inc.，担任总裁、首席执行官和董事。加入Benitec Biopharma Inc.之前，他曾担任以下公司的董事会成员。他曾担任Teva Pharmaceutical Industries公司（Teva公司）的公司副总裁，负责全球品牌产品（从2011年10月到2012年5月），以及Cephalon公司的首席执行官（从2010年12月到2011年10月）（2011年10月Teva公司收购Cephalon公司之前）。他于1991年加入Cephalon公司，也担任首席财务官（从1996年到2009年12月）、首席运营官（从2010年1月到2010年12月）。他目前任职于Alexza Pharmaceuticals公司（NASDAQ：ALXA）（2013年至今）、Benitec Biopharma公司（ASX：BLT）（2013年至今）、EPIRUS Biopharmaceuticals公司（2013年至今），、Forward Pharma公司（丹麦）（2012年至今），以及Stemline Therapeutics公司（NASDAQ：STML）（2012年至今）的董事会。此前，他曾任职于Celator Pharmaceuticals公司（2006年至2010年）、Encysive Pharmaceuticals公司（2004年至2008年）、Lorus Therapeutics公司（加拿大）（2003年至2009年）、Mesoblast Limited公司（澳大利亚） （ASX：MSB）（2010年至2012年）的董事会。他于1976年获得康奈尔大学（ Cornell University ）的化学学士学位，并于1980年获得西北大学凯洛格商学院（Northwestern University Kellogg School of Management）的管理硕士学位。
- J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010, Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant.
- Edward Smith
-
Edward Smith担任Reunion Neuroscience，Inc.的首席财务官，该公司是一家专注于治疗抑郁症和其他心理健康障碍的生物制药公司。在加入Reunion公司之前，Smith先生曾担任首席财务官，并曾将LAVA Therapeutics N.V.（纳斯达克：LVTX）、Marinus Pharmaceuticals, Inc.（纳斯达克）（TERM4）（TERM3）（TERM4：MRNS）和PolyMedix，Inc.（纳斯达克：PYMX）上市。在此之前，他是InKine Pharmaceutical Company，Inc.的财务执行董事，现在是Valeant Pharmaceuticals International Inc.的一部分。在他职业生涯的早期，他在公共会计领域担任过越来越多的职责，最近在德勤的审计实践中担任过多个职位。
Edward Smith serves as Chief Financial Officer of Reunion Neuroscience, Inc., a biopharmaceutical company focused on treating depression and other mental health disorders. Prior to joining Reunion, Mr. Smith served as CFO and took public LAVA Therapeutics N.V. (Nasdaq: LVTX), Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) and PolyMedix, Inc. (Nasdaq: PYMX). Prior to that, he was executive director of finance at InKine Pharmaceutical Company, Inc., now part of Valeant Pharmaceuticals International Inc. Earlier in his career, he held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte. - Edward Smith担任Reunion Neuroscience，Inc.的首席财务官，该公司是一家专注于治疗抑郁症和其他心理健康障碍的生物制药公司。在加入Reunion公司之前，Smith先生曾担任首席财务官，并曾将LAVA Therapeutics N.V.（纳斯达克：LVTX）、Marinus Pharmaceuticals, Inc.（纳斯达克）（TERM4）（TERM3）（TERM4：MRNS）和PolyMedix，Inc.（纳斯达克：PYMX）上市。在此之前，他是InKine Pharmaceutical Company，Inc.的财务执行董事，现在是Valeant Pharmaceuticals International Inc.的一部分。在他职业生涯的早期，他在公共会计领域担任过越来越多的职责，最近在德勤的审计实践中担任过多个职位。
- Edward Smith serves as Chief Financial Officer of Reunion Neuroscience, Inc., a biopharmaceutical company focused on treating depression and other mental health disorders. Prior to joining Reunion, Mr. Smith served as CFO and took public LAVA Therapeutics N.V. (Nasdaq: LVTX), Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) and PolyMedix, Inc. (Nasdaq: PYMX). Prior to that, he was executive director of finance at InKine Pharmaceutical Company, Inc., now part of Valeant Pharmaceuticals International Inc. Earlier in his career, he held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte.
- Kishen Mehta
-
Kishen Mehta自2024年6月起担任董事。Mehta先生是Montanova的Averill和Averill Madison策略的首席投资官兼投资组合经理。Mehta先生在医疗保健行业拥有超过15年的经验。自2022年9月起，Mehta先生担任Biohaven Ltd.（NYSE：BHVN）的董事，该公司是一家专注于免疫学、神经科学和肿瘤学治疗的生物制药公司，在此之前，曾于2021年6月至2022年9月担任其前身公司生物医药控股有限公司的董事。从2021年开始，Mehta先生还担任Montanova所属的四家在纳斯达克上市的特殊目的收购公司的总裁兼董事，这些公司分别是：Social Capital Suvretta Holdings Corp. I（Mehta先生因企业合并而于2022年8月从该公司辞职）、Social Capital Suvretta Holdings Corp. II（已于2023年5月停止运营）、Social Capital Suvretta Holdings Corp. III（Mehta先生因企业合并于2022年7月从该公司辞职），和Social Capital Suvretta Holdings Corp. IV（已于2023年5月停止运营），也是MedStaff Technologies，Inc.的董事会成员。在成为Montanova投资策略部门的投资组合经理之前，他曾担任BiohavenPharmaceuticals，Inc.的战略顾问，在那里他就各种业务发展、公司战略和资本结构决策为该公司提供建议。
Kishen Mehta has been a director since June 2024. Mr. Mehta is the Chief Investment Officer and Portfolio Manager of the Averill and Averill Madison strategies at Montanova. Mr. Mehta has over 15 years of experience in the healthcare industry. Since September 2022, Mr. Mehta has served as a director of Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on therapeutics in immunology, neuroscience, and oncology, and prior to that served as a director of its predecessor company, Biohaven Pharmaceutical Holding Company Ltd., from June 2021 until September 2022. Beginning in 2021, Mr. Mehta also served as President and a director of four Nasdaq listed special purpose acquisition companies affiliated with Montanova, Social Capital Suvretta Holdings Corp. I (from which Mr. Mehta resigned in August 2022 in connection with its business combination), Social Capital Suvretta Holdings Corp. II (which ceased operations in May 2023), Social Capital Suvretta Holdings Corp. III (from which Mr. Mehta resigned in July 2022 in connection with its business combination), and Social Capital Suvretta Holdings Corp. IV (which ceased operations in May 2023) and is also on the board of directors of MedStaff Technologies, Inc. Prior to becoming the Portfolio Manager of the investment strategy at Montanova , he served as a strategic advisor to Biohaven Pharmaceuticals, Inc. where he advised the firm on various business development, corporate strategy, and capital structure decisions. - Kishen Mehta自2024年6月起担任董事。Mehta先生是Montanova的Averill和Averill Madison策略的首席投资官兼投资组合经理。Mehta先生在医疗保健行业拥有超过15年的经验。自2022年9月起，Mehta先生担任Biohaven Ltd.（NYSE：BHVN）的董事，该公司是一家专注于免疫学、神经科学和肿瘤学治疗的生物制药公司，在此之前，曾于2021年6月至2022年9月担任其前身公司生物医药控股有限公司的董事。从2021年开始，Mehta先生还担任Montanova所属的四家在纳斯达克上市的特殊目的收购公司的总裁兼董事，这些公司分别是：Social Capital Suvretta Holdings Corp. I（Mehta先生因企业合并而于2022年8月从该公司辞职）、Social Capital Suvretta Holdings Corp. II（已于2023年5月停止运营）、Social Capital Suvretta Holdings Corp. III（Mehta先生因企业合并于2022年7月从该公司辞职），和Social Capital Suvretta Holdings Corp. IV（已于2023年5月停止运营），也是MedStaff Technologies，Inc.的董事会成员。在成为Montanova投资策略部门的投资组合经理之前，他曾担任BiohavenPharmaceuticals，Inc.的战略顾问，在那里他就各种业务发展、公司战略和资本结构决策为该公司提供建议。
- Kishen Mehta has been a director since June 2024. Mr. Mehta is the Chief Investment Officer and Portfolio Manager of the Averill and Averill Madison strategies at Montanova. Mr. Mehta has over 15 years of experience in the healthcare industry. Since September 2022, Mr. Mehta has served as a director of Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on therapeutics in immunology, neuroscience, and oncology, and prior to that served as a director of its predecessor company, Biohaven Pharmaceutical Holding Company Ltd., from June 2021 until September 2022. Beginning in 2021, Mr. Mehta also served as President and a director of four Nasdaq listed special purpose acquisition companies affiliated with Montanova, Social Capital Suvretta Holdings Corp. I (from which Mr. Mehta resigned in August 2022 in connection with its business combination), Social Capital Suvretta Holdings Corp. II (which ceased operations in May 2023), Social Capital Suvretta Holdings Corp. III (from which Mr. Mehta resigned in July 2022 in connection with its business combination), and Social Capital Suvretta Holdings Corp. IV (which ceased operations in May 2023) and is also on the board of directors of MedStaff Technologies, Inc. Prior to becoming the Portfolio Manager of the investment strategy at Montanova , he served as a strategic advisor to Biohaven Pharmaceuticals, Inc. where he advised the firm on various business development, corporate strategy, and capital structure decisions.
- David Friedman
-
David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology. - David Friedman自2025年12月起担任董事会成员。自2020年1月起，弗里德曼博士担任Suvretta Capital Management，LLC或Suvretta Capital的董事总经理和高级分析师。在加入Suvretta Capital之前，Friedman博士曾担任Scopia Capital Management LP的医疗保健分析师，并曾在摩根士丹利 & Co. LLC从事生物技术股票研究工作。弗里德曼博士在杜克大学获得生物学学士学位，在匹兹堡大学医学院获得医学博士学位，在哈佛大学比尼斯学院获得工商管理硕士学位。
- David Friedman has been a member of Avalyn Pharma Inc.'s board of directors since April 2025. Since January 2020, Dr. Friedman has served as a Managing Director and Senior Analyst at Suvretta Capital Management, LLC, or Suvretta, for its healthcare and biotech focused Averill investment strategies. Prior to Suvretta, Dr. Friedman was a Healthcare Analyst at Scopia Capital Management from the beginning of 2014 to December 2019 and worked in biotechnology equity research at Morgan Stanley from 2006 to 2009 and 2010 to 2014. Dr. Friedman currently serves on the board of directors of Veradermics, Inc. (Nasdaq: MANE), Click Therapeutics, Inc., and Sapphiros. Dr. Friedman received an M.B.A. from Harvard Business School, an M.D. from University of Pittsburgh School of Medicine and a B.S. from Duke University in Biology.
- Sharon Mates
-
Sharon Mates，哲学博士，自2013年合并起一直是公司的主席，总监兼首席执行官，而自2002年6月起一直是ITI的董事会主席，总裁及首席执行官。她于2002年5月联合创立了TIT。在那之前，她曾是Functional Genetics的一位联合创始人，并从2000年12月起知道2003年8月期间担任其主席兼首席执行官。1989年至1998年她曾是North American Vaccine Inc.及其前身公司的总裁及董事会一员。她任职于几个董事会，而于目前完成了New York Biotechnology Association董事会的一个董事会成员资格和一个两年的主席任职。她还任职于哈佛大学公共健康的社会和健康中心咨询委员会，University of Maryland生物科技学院的监事会，以及Gilda's Club of New York的董事会。在其职业生涯早期，她花了几年作为一名研究分析师和投资银行家，以及作为一位针对生命科学产业的顾问。她从Ohio State University接受其学士学位，从University of Washington接受其博士学位，并在The Massachusetts General Hospital和Harvard Medical School完成了她的博士后。
Sharon Mates has been a director since November 2025 and was appointed as the Board's Lead Independent Director in May 2026. Dr. Mates served as the Chairman, Chief Executive Officer, and Co founder of Intra Cellular Therapies Inc. (ITI) from June 2002 until its acquisition by Johnson & Johnson (JNJ) in April 2025. Intra Cellular Therapies focused on developing medicines for mental health disorders like bipolar disorder, depression and schizophrenia and received U.S. Food and Drug Administration ("FDA") approval for its novel antipsychotic CAPLYTA in 2019 prior to its 2025 acquisition for approximately $14.6 billion by JNJ. She has served on several not for profit boards. Dr. Mates is also a director of Medincell, a biopharmaceutical company in France (Euronext: MEDCL) and is also on the board of directors of Seaport Therapeutics, Inc. (Nasdaq: SPTX). She has also served on advisory councils affiliated with Harvard School of Public Health and the University of Maryland Biotechnology Institute. Dr. Mates received a B.S. from Ohio State University, a Ph.D. from the University of Washington and completed her postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School. - Sharon Mates，哲学博士，自2013年合并起一直是公司的主席，总监兼首席执行官，而自2002年6月起一直是ITI的董事会主席，总裁及首席执行官。她于2002年5月联合创立了TIT。在那之前，她曾是Functional Genetics的一位联合创始人，并从2000年12月起知道2003年8月期间担任其主席兼首席执行官。1989年至1998年她曾是North American Vaccine Inc.及其前身公司的总裁及董事会一员。她任职于几个董事会，而于目前完成了New York Biotechnology Association董事会的一个董事会成员资格和一个两年的主席任职。她还任职于哈佛大学公共健康的社会和健康中心咨询委员会，University of Maryland生物科技学院的监事会，以及Gilda's Club of New York的董事会。在其职业生涯早期，她花了几年作为一名研究分析师和投资银行家，以及作为一位针对生命科学产业的顾问。她从Ohio State University接受其学士学位，从University of Washington接受其博士学位，并在The Massachusetts General Hospital和Harvard Medical School完成了她的博士后。
- Sharon Mates has been a director since November 2025 and was appointed as the Board's Lead Independent Director in May 2026. Dr. Mates served as the Chairman, Chief Executive Officer, and Co founder of Intra Cellular Therapies Inc. (ITI) from June 2002 until its acquisition by Johnson & Johnson (JNJ) in April 2025. Intra Cellular Therapies focused on developing medicines for mental health disorders like bipolar disorder, depression and schizophrenia and received U.S. Food and Drug Administration ("FDA") approval for its novel antipsychotic CAPLYTA in 2019 prior to its 2025 acquisition for approximately $14.6 billion by JNJ. She has served on several not for profit boards. Dr. Mates is also a director of Medincell, a biopharmaceutical company in France (Euronext: MEDCL) and is also on the board of directors of Seaport Therapeutics, Inc. (Nasdaq: SPTX). She has also served on advisory councils affiliated with Harvard School of Public Health and the University of Maryland Biotechnology Institute. Dr. Mates received a B.S. from Ohio State University, a Ph.D. from the University of Washington and completed her postdoctoral fellowships at Massachusetts General Hospital and Harvard Medical School.
高管简历
中英对照 | 中文 | 英文- Megan Boston
Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 15 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub committees particularly in the area of finance and risk management. Specifically, Ms. Boston was a Director of Benitec from August 2016 to May 2026, Executive Director from June 2018 to December 31, 2024 and Benitec Biopharma Inc.'s Chief Financial Officer since January 1, 2025. Ms. Boston is also Benitec Biopharma Inc.'s Secretary. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange and held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.- Megan Boston，自2016年8月16日以来，她担任董事职务。2014年4月至2016年7月，她曾担任Omni Market Tide Limited（澳交所上市的科技公司）的董事总经理。2014年4月至2015年6月，她曾担任GRT Exchange（澳大利亚科技公司）的首席执行官。2010年以来，她一直担任澳大利亚成人多元文化和教育服务的董事兼副主席，以及the Victorian Human Rights and Equal Opportunity Commission的董事会成员和审计和风险委员会主席。此前，她曾担任Beyond Medical Education（澳大利亚维多利亚地区的全科医生培训服务的供应商）的董事会成员兼财政、审计和风险委员会主席。她是澳大利亚特许会计师。
- Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 15 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub committees particularly in the area of finance and risk management. Specifically, Ms. Boston was a Director of Benitec from August 2016 to May 2026, Executive Director from June 2018 to December 31, 2024 and Benitec Biopharma Inc.'s Chief Financial Officer since January 1, 2025. Ms. Boston is also Benitec Biopharma Inc.'s Secretary. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange and held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors.
- Jerel Banks
Jerel Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
Jerel Banks has been a Director since October 2016, Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. Dr. Banks' experience in the healthcare industry and finance provides valuable experience and guidance to the Board.- Jerel Banks，2016年10月25日以来，他一直担任董事职务。他是Nant Capital, LLC的首席投资官。加入Nant Capital, LLC之前，他曾担任Franklin Templeton Investments的富兰克林生物技术探索基金（the Franklin Biotechnology Discovery Fund）的副总裁、投资组合经理、研究分析师（2012年至2015年）。他目前担任Genos Research, Inc的董事。任职Franklin Templeton Investments之前，他曾担任Sectoral Asset Management的生物技术股票研究分析师（2011年至2012年）。2008年至2011年，他曾担任Apothecary Capital（得克萨斯州沃思堡的巴斯家族的家族投资办公室的医疗投资管理团队）的生物技术股票研究分析师。他的投资管理职业生涯始于担任Capital Research Company的医疗证券研究助理，在那里他曾担任证券研究团队的成员（2006年至2008年）。他持有the Brown University School of Medicine的医学博士学位、Brown University的有机化学博士学位，以及Princeton University的化学学士学位。
- Jerel Banks has been a Director since October 2016, Chairman of Benitec Biopharma Inc.'s Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. Dr. Banks' experience in the healthcare industry and finance provides valuable experience and guidance to the Board.
- Sophie Mukadam
Sophie Mukadam自2025年1月1日起担任公司首席运营官，在此之前，自2021年起担任Benitec Biopharma公司项目管理副总监，此前曾在2019年至2021年期间担任高级项目经理。2018年至2019年期间，Mukadam女士在Premier Consulting（前身为Regulatory Professionals，Inc.）担任监管事务专业人员。在从事项目管理和监管事务领域的工作之前，Mukadam女士深入参与了基础研究和开发活动，这些活动是推进广泛的研究性治疗项目的基础。2003年至2018年期间，Mukadam女士曾在基因泰克（罗氏集团成员）、百时美施贵宝（前身为Kosan Biosciences Inc.）和辉瑞（前身为Vicuron Pharmaceuticals）担任科研职务，她的许多主要贡献都出现在科学文献中。Mukadam女士拥有加州大学伯克利分校的分子和细胞生物学学士学位，并获得了华盛顿大学和加州大学圣地亚哥分校的生物技术项目管理证书。
Sophie Mukadam has served as the Company's Chief Operating Officer since January 1, 2025 and, prior to that, served as Associate Director, Program Management at Benitec Biopharma Inc. since 2021 and previously served as Senior Program Manager between 2019 and 2021. Between 2018 and 2019, Ms. Mukadam served as a regulatory affairs professional at Premier Consulting (formerly Regulatory Professionals, Inc.). Prior to her work in the areas of program management and regulatory affairs, Ms. Mukadam was deeply engaged in fundamental research and development activities underlying the advancement of a broad range of investigational therapeutic programs. Between 2003 and 2018, Ms. Mukadam held scientific research positions at Genentech (A Member of the Roche Group), Bristol Myers Squibb (formerly Kosan Biosciences Inc.), and Pfizer (formerly Vicuron Pharmaceuticals), with many of her principal contributions represented in the scientific literature. Ms. Mukadam holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and she has earned a Certificate in Project Management for Biotechnology from the University of Washington and the University of California, San Diego.- Sophie Mukadam自2025年1月1日起担任公司首席运营官，在此之前，自2021年起担任Benitec Biopharma公司项目管理副总监，此前曾在2019年至2021年期间担任高级项目经理。2018年至2019年期间，Mukadam女士在Premier Consulting（前身为Regulatory Professionals，Inc.）担任监管事务专业人员。在从事项目管理和监管事务领域的工作之前，Mukadam女士深入参与了基础研究和开发活动，这些活动是推进广泛的研究性治疗项目的基础。2003年至2018年期间，Mukadam女士曾在基因泰克（罗氏集团成员）、百时美施贵宝（前身为Kosan Biosciences Inc.）和辉瑞（前身为Vicuron Pharmaceuticals）担任科研职务，她的许多主要贡献都出现在科学文献中。Mukadam女士拥有加州大学伯克利分校的分子和细胞生物学学士学位，并获得了华盛顿大学和加州大学圣地亚哥分校的生物技术项目管理证书。
- Sophie Mukadam has served as the Company's Chief Operating Officer since January 1, 2025 and, prior to that, served as Associate Director, Program Management at Benitec Biopharma Inc. since 2021 and previously served as Senior Program Manager between 2019 and 2021. Between 2018 and 2019, Ms. Mukadam served as a regulatory affairs professional at Premier Consulting (formerly Regulatory Professionals, Inc.). Prior to her work in the areas of program management and regulatory affairs, Ms. Mukadam was deeply engaged in fundamental research and development activities underlying the advancement of a broad range of investigational therapeutic programs. Between 2003 and 2018, Ms. Mukadam held scientific research positions at Genentech (A Member of the Roche Group), Bristol Myers Squibb (formerly Kosan Biosciences Inc.), and Pfizer (formerly Vicuron Pharmaceuticals), with many of her principal contributions represented in the scientific literature. Ms. Mukadam holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and she has earned a Certificate in Project Management for Biotechnology from the University of Washington and the University of California, San Diego.